Nicola_K_photos / Shutterstock.com

30 April 2024NewsBiotechnologyLiz Hockley

Amgen and Sandoz settle dispute over blockbuster bone condition drugs

Agreement clears the way for Sandoz to launch denosumab biosimilars in May 2025 | Dispute over multiple patents covering Prolia and Xgeva resolved.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Amgen v Sanofi/Regeneron in Japan: Function, sequence, mechanism

19 March 2024 Amgen patents declared valid in Germany and Japan have also been deemed invalid by the European Patent Office, US Supreme Court, and in a separate Japan decision: but why? Takanori Abe of Abe & Partners examines the details.

Biotechnology

USPTO backs Wands factors post-Amgen enablement loss

11 January 2024 SCOTUS ignored Fed Circ cases and so-called Wands factors in reaching enablement decision | Pivotal question left unanswered | New guidance ‘provides clarity’ and reinforces status quo on enablement decisions.

More on this story

Amgen v Sanofi/Regeneron in Japan: Function, sequence, mechanism

19 March 2024 Amgen patents declared valid in Germany and Japan have also been deemed invalid by the European Patent Office, US Supreme Court, and in a separate Japan decision: but why? Takanori Abe of Abe & Partners examines the details.

Biotechnology

USPTO backs Wands factors post-Amgen enablement loss

11 January 2024 SCOTUS ignored Fed Circ cases and so-called Wands factors in reaching enablement decision | Pivotal question left unanswered | New guidance ‘provides clarity’ and reinforces status quo on enablement decisions.

More on this story

Amgen v Sanofi/Regeneron in Japan: Function, sequence, mechanism

19 March 2024 Amgen patents declared valid in Germany and Japan have also been deemed invalid by the European Patent Office, US Supreme Court, and in a separate Japan decision: but why? Takanori Abe of Abe & Partners examines the details.

Biotechnology

USPTO backs Wands factors post-Amgen enablement loss

11 January 2024 SCOTUS ignored Fed Circ cases and so-called Wands factors in reaching enablement decision | Pivotal question left unanswered | New guidance ‘provides clarity’ and reinforces status quo on enablement decisions.

More features

Novartis shields eye-drop patent at European Patent Office

CREATES Act unfairly tips the scales to generics

LSPN launches its first-ever US awards to celebrate life sciences leaders

Pharma giants seek closure on COVID-19 vaccine rows

How Inhibrx defended a $450m damages suit

Foley & Lardner adds litigation and transaction expert in New York

UPC deals further blow to Dexcom in glucose monitor dispute with Abbott

‘A marathon and a sprint at the same time’: How we won $452m damages